American Academy of Neurology (AAN)
April 2023
Integrated Safety Summary From Phase 3 Clinical Trials of IPX203, an Extended-Release Carbidopa-Levodopa Formulation, in Parkinson’s Disease
Hubert H. Fernandez, Robert A. Hauser, Vanessa K. Hinson, Nirav Pavasia, Eric Molho, Leonid Zeitlin, Hester Visser, Richard D’Souza
The International Parkinson and Movement Disorder Society (MDS)
September 2022
Dose Conversion From Immediate-Release Carbidopa-Levodopa to IPX203 (ER CD-LD) in Parkinson’s Disease Patients With Motor Fluctuations
Robert A. Hauser, Alberto J. Espay, William Ondo, Beth Safirstein, Henry Moore, Rajeev Kumar, Ghazal Banisadr, Stanley Fisher
The International Parkinson and Movement Disorder Society (MDS)
September 2022
Duration of Continuous “Good On” Intervals and Number of Motor Fluctuations: IPX203 (Extended-Release Carbidopa-Levodopa) vs Immediate-Release Carbidopa-Levodopa in Parkinson’s Disease Patients With Motor Fluctuations
Robert A. Hauser, Hubert H. Fernandez, Jason Aldred, Carlos Singer, Holly Shill, Hester Visser, Richard D’Souza
Advanced Therapeutics in Movement & Related Disorders (ATMRD)
June 2022
Duration of Benefit per Dose: Post Hoc Analysis of “Good On” Time per Dose for IPX203 vs IR CD-LD in the RISE-PD Phase 3 Trial
Robert A. Hauser, Hubert H. Fernandez, Kevin Klos, Susan Criswell, Neepa Patel, Ghazal Banisadr, Stanley Fisher
Pan American Parkinson’s Disease and Movement Disorders Congress (MDS-PAS)
May 2022
Design of Better Oral Levodopa Delivery: Formulation Strategy of IPX203, an Investigational Extended-Release Carbidopa-Levodopa
Rohit Dhall, Pinky Agarwal, Camilla Kilbane, Ramon Gil, Aaron Ellenbogen, Ghazal Banisadr, Richard D’Souza, Peter LeWitt